
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lead Product(s) : Selenium Methionine
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimal Selenium for Bowel Polyps (OSCAR)
Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Adenoma.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
July 07, 2021
Lead Product(s) : Selenium Methionine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Cancer Trials New Zealand | Counties Manukau Health | Waikato Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Selenium Methionine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Mohammed Milhem
Deal Size : Inapplicable
Deal Type : Inapplicable
SLM + Axitinib for Clear Cell RCC
Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
August 28, 2015
Lead Product(s) : Selenium Methionine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Mohammed Milhem
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Selenium Methionine
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : IBSA Institut Biochimique
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT
Details : Selenomethionine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroiditis, Autoimmune.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
November 27, 2014
Lead Product(s) : Selenium Methionine
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : IBSA Institut Biochimique
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All